{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,3,14]],"date-time":"2024-03-14T00:42:39Z","timestamp":1710376959147},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,1,8]],"date-time":"2024-01-08T00:00:00Z","timestamp":1704672000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,1,8]],"date-time":"2024-01-08T00:00:00Z","timestamp":1704672000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["High Blood Press Cardiovasc Prev"],"DOI":"10.1007\/s40292-023-00616-y","type":"journal-article","created":{"date-parts":[[2024,1,8]],"date-time":"2024-01-08T08:02:04Z","timestamp":1704700924000},"page":"23-30","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Comparison of vitamin K and non-vitamin K oral anticoagulants and the bleeding frequency in the emergency department"],"prefix":"10.1007","volume":"31","author":[{"given":"Tomo","family":"Svagu\u0161a","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stjepan","family":"\u0160imi\u0107","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Filip","family":"Grabant","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tatjana","family":"Kere\u0161","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ognjen","family":"\u010can\u010darevi\u0107","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Frane","family":"Pai\u0107","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Danijela","family":"Grizelj","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aleksandar","family":"Blivajs","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomislav","family":"Bulum","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ingrid","family":"Prka\u010din","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,1,8]]},"reference":[{"key":"616_CR1","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1161\/CIRCULATIONAHA.114.013267","volume":"132","author":"M Sharma","year":"2015","unstructured":"Sharma M, Cornelius VR, Patel JP, Davies JG, Molokhia M. Efficacy and harms of direct oral anticoagulants in the elderly for stroke prevention in atrial fibrillation and secondary prevention of venous thromboembolism: systematic review and meta-analysis. Circulation. 2015;132:194\u2013204. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.114.013267.","journal-title":"Circulation"},{"key":"616_CR2","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1093\/europace\/euab303","volume":"24","author":"M Grymonprez","year":"2022","unstructured":"Grymonprez M, Simoens C, Steurbaut S, De Backer TKL, Lahousse L. Worldwide trends in oral anticoagulant use in patients with atrial fibrillation from 2010 to 2018: a systematic review and meta-analysis. Europace. 2022;24:887\u201398. https:\/\/doi.org\/10.1093\/europace\/euab303.","journal-title":"Europace"},{"key":"616_CR3","doi-asserted-by":"publisher","unstructured":"Ageno W, Gallus AS, Wittkowsky A, Crowther M, Hylek EM, Palareti G. Oral anticoagulant therapy: antithrombotic therapy and prevention of thrombosis, 9th edn: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2012;141(2Suppl):e44S\u2013e88S. https:\/\/doi.org\/10.1378\/chest.11-2292","DOI":"10.1378\/chest.11-2292"},{"key":"616_CR4","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1111\/j.1365-2125.2006.02806.x","volume":"62","author":"M Pirmohamed","year":"2006","unstructured":"Pirmohamed M. Warfarin: almost 60 years and still causing problems. Br J Clin Pharmacol. 2006;62:509\u201311. https:\/\/doi.org\/10.1111\/j.1365-2125.2006.02806.x.","journal-title":"Br J Clin Pharmacol"},{"key":"616_CR5","doi-asserted-by":"publisher","first-page":"40","DOI":"10.15420\/ecr.2017:11:2","volume":"12","author":"J Sikorska","year":"2017","unstructured":"Sikorska J, Uprichard J. Direct oral anticoagulants: a quick guide. Eur Cardiol Rev. 2017;12:40\u20135. https:\/\/doi.org\/10.15420\/ecr.2017:11:2.","journal-title":"Eur Cardiol Rev."},{"key":"616_CR6","doi-asserted-by":"publisher","first-page":"847","DOI":"10.3949\/ccjm.82a.14052","volume":"82","author":"B Roca","year":"2015","unstructured":"Roca B, Roca M. The new oral anticoagulants: reasonable alternatives to warfarin. Cleve Clin J Med. 2015;82:847\u201354. https:\/\/doi.org\/10.3949\/ccjm.82a.14052.","journal-title":"Cleve Clin J Med"},{"key":"616_CR7","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1177\/1747493019895654","volume":"12","author":"P Kermer","year":"2017","unstructured":"Kermer P, Eschenfelder CC, Diener HC, Grond M, Abdalla Y, Althaus K, Berrouschot J, Cang\u00fcr H, Daffertshofer M, Edelbusch S, Gr\u00f6schel K, Haase CG, Harloff A, Held V, Kauert A, Kraft P, Lenz A, M\u00fcllges W, Obermann M, Partowi S, Purrucker J, Ringleb PA, R\u00f6ther J, Rossi R, Sch\u00e4fer N, Schneider A, Schuppner R, Seitz RJ, Szabo K, Wruck R. Antagonizing dabigatran by idarucizumab in cases of ischemic stroke or intracranial hemorrhage in Germany\u2014a national case collection. Int J Stroke. 2017;12:383\u201391. https:\/\/doi.org\/10.1177\/1747493019895654.","journal-title":"Int J Stroke"},{"issue":"1","key":"616_CR8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s40262-013-0100-7","volume":"53","author":"W Mueck","year":"2014","unstructured":"Mueck W, Stampfuss J, Kubitza D, Becka M. Clinical pharmacokinetic and pharmacodynamic profile of rivaroxaban. Clin Pharmacokinet. 2014;53(1):1\u201316. https:\/\/doi.org\/10.1007\/s40262-013-0100-7.","journal-title":"Clin Pharmacokinet"},{"key":"616_CR9","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1016\/j.nefro.2016.08.006","volume":"37","author":"L Belmar Vega","year":"2017","unstructured":"Belmar Vega L, de Francisco \u00c1LM, da Silva JB, Galv\u00e1n Espinoza L, Fern\u00e1ndez FG. New oral anticoagulants in patients with chronic kidney disease. Nefrologia. 2017;37:244\u201352. https:\/\/doi.org\/10.1016\/j.nefro.2016.08.006.","journal-title":"Nefrologia"},{"key":"616_CR10","doi-asserted-by":"publisher","unstructured":"Byol W, Garonzik S, Boyd RA, Frost CE. Apixaban: a clinical pharmacokinetic and pharmacodynamic review. Clin Pharmacokinet. 2019;58:1265\u201379. https:\/\/doi.org\/10.1007\/s40262-019-00775-z","DOI":"10.1007\/s40262-019-00775-z"},{"key":"616_CR11","doi-asserted-by":"publisher","first-page":"107602961986853","DOI":"10.1177\/1076029619868535","volume":"25","author":"CI Coleman","year":"2019","unstructured":"Coleman CI, Kreutz R, Sood N, Bunz TJ, Meinecke AK, Eriksson D, Baker WL. Rivaroxaban\u2019s impact on renal decline in patients with nonvalvular atrial fibrillation: a US MarketScan Claims Database Analysis. Clin Appl Thromb Hemost. 2019;25:1076029619868535. https:\/\/doi.org\/10.1177\/1076029619868535.","journal-title":"Clin Appl Thromb Hemost"},{"key":"616_CR12","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1016\/S0140-6736(13)62343-0","volume":"383","author":"CT Ruff","year":"2014","unstructured":"Ruff CT, Giugliano RP, Braunwald E, Hoffman EB, Deenadayalu N, Ezekowitz MD, Camm AJ, Weitz JI, Lewis BS, Parkhomenko A, Yamashita T, Antman EM. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomized trials. Lancet. 2014;383:955\u201362. https:\/\/doi.org\/10.1016\/S0140-6736(13)62343-0.","journal-title":"Lancet"},{"key":"616_CR13","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/s11239-015-1311-6","volume":"41","author":"JA Heit","year":"2016","unstructured":"Heit JA, Spencer FA, White RH. The epidemiology of venous thromboembolism. J Thromb Thrombolysis. 2016;41:3\u201314. https:\/\/doi.org\/10.1007\/s11239-015-1311-6.","journal-title":"J Thromb Thrombolysis"},{"key":"616_CR14","doi-asserted-by":"publisher","unstructured":"Scharrer S, Primas C, Eichinge S, Tonko S, Kutschera M, Koch R, Blesl A, Reinisch W, Mayer A, Haas T, Austrian IBD Study Group. Inflammatory bowel disease and risk of major bleeding during anticoagulation for venous thromboembolism. Inflamm Bowel Dis. 2021;27:1773\u201383. https:\/\/doi.org\/10.1093\/ibd\/izaa337","DOI":"10.1093\/ibd\/izaa337"},{"key":"616_CR15","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1053\/j.ajkd.2010.02.337","volume":"55","author":"AS Levey","year":"2010","unstructured":"Levey AS, Stevens LA. Estimating GFR using the CKD epidemiology collaboration (CKD-EPI) creatinine equation: more accurate GFR estimates, lower CKD prevalence estimates, and better risk predictions. Am J Kidney Dis. 2010;55:622\u20137. https:\/\/doi.org\/10.1053\/j.ajkd.2010.02.337.","journal-title":"Am J Kidney Dis"},{"key":"616_CR16","doi-asserted-by":"publisher","first-page":"68","DOI":"10.22514\/SV131.032017.11","volume":"13","author":"I Prka\u010din","year":"2017","unstructured":"Prka\u010din I, Nesek Adam V, Cavri\u0107 G, Svagu\u0161a T, Kova\u010di\u0107 M, Kova\u010devi\u0107 I. Direct oral anticoagulant therapy and drug interactions in patients with atrial fibrillation. Signa Vitae. 2017;13:68\u201370. https:\/\/doi.org\/10.22514\/SV131.032017.11.","journal-title":"Signa Vitae"},{"key":"616_CR17","doi-asserted-by":"publisher","first-page":"1144","DOI":"10.2215\/CJN.13811217","volume":"13","author":"J Shin","year":"2018","unstructured":"Shin J, Secora A, Alexander G, Inker L, Coresh J, Chang A, Grams ME. Risks and benefits of direct oral anticoagulants across the spectrum of GFR among incident and prevalent patients with atrial fibrillation. Clin J Am Soc Nephrol. 2018;13:1144\u201352. https:\/\/doi.org\/10.2215\/CJN.13811217.","journal-title":"Clin J Am Soc Nephrol"},{"key":"616_CR18","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.114.001179","volume":"3","author":"GYH Lip","year":"2014","unstructured":"Lip GYH, Al-Khatib SM, Cosi FG, Banerjee A, Savelieva I, Ruskin J, Blendea D, Nattel S, De Bono J, Conroy JM, Hess PL, Guasch E, Halperin JL, Kirchhof P, Cosio MDG, Camm AJ. Contemporary management of atrial fibrillation: what can clinical registries tell us about stroke prevention and current therapeutic approaches? J Am Heart Assoc. 2014;3: e001179. https:\/\/doi.org\/10.1161\/JAHA.114.001179.","journal-title":"J Am Heart Assoc"},{"key":"616_CR19","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1016\/j.amjmed.2018.12.023","volume":"132","author":"DJ Graham","year":"2019","unstructured":"Graham DJ, Baro E, Zhang R, Liao J, Wernecke M, Reichman ME, Hu M, Illoh O, Wei Y, Goulding MR, Chillarige Y, Southworth MR, MaCurdy TE, Kelman JA. Comparative stroke, bleeding, and mortality risks in older medicare patients treated with oral anticoagulants for nonvalvular atrial fibrillation. Am J Med. 2019;132:596\u2013604. https:\/\/doi.org\/10.1016\/j.amjmed.2018.12.023.","journal-title":"Am J Med"},{"key":"616_CR20","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1093\/ehjcvp\/pvz086","volume":"6","author":"OW Rutherford","year":"2020","unstructured":"Rutherford OW, Jonasson C, Ghanima W, S\u00f6derdahl F, Halvorsen S. Comparison of dabigatran, rivaroxaban, and apixaban for effectiveness and safety in atrial fibrillation: a nationwide cohort study. Eur Heart J Cardiovasc Pharmacother. 2020;6:75\u201385. https:\/\/doi.org\/10.1093\/ehjcvp\/pvz086.","journal-title":"Eur Heart J Cardiovasc Pharmacother."},{"key":"616_CR21","doi-asserted-by":"publisher","unstructured":"Steinberg B, Shrader P, Thomas L, Ansell J, Fonarow G, Gersh BJ, Kowey PR, Mahaffey KW, Naccarelli G, Reiffel J, Singer DE, Peterson ED, Piccini JP, ORBIT-AF Investigators. Off-label dosing of non-vitamin K antagonist oral anticoagulants and adverse outcomes. The ORBIT-AF II Registry. J Am Coll Cardiol. 2016;68:2597\u2013604. https:\/\/doi.org\/10.1016\/j.jacc.2016.09.966.","DOI":"10.1016\/j.jacc.2016.09.966"},{"key":"616_CR22","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1016\/j.cgh.2019.05.056","volume":"18","author":"ZC Gu","year":"2020","unstructured":"Gu ZC, Wei A-H, Zhang C, Wang X-H, Zhang L, Shen L, Li Z, Pan MM, Liu X-Y, Pu J, Lin H-W. Risk of major gastrointestinal bleeding with new vs conventional oral anticoagulants: a systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2020;18:792\u20139. https:\/\/doi.org\/10.1016\/j.cgh.2019.05.056.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"616_CR23","doi-asserted-by":"publisher","first-page":"550","DOI":"10.3325\/cmj.2009.50.550","volume":"50","author":"I Jukic","year":"2009","unstructured":"Jukic I, Bingulac-Popovic J, Dogic V, Babic I, Culej J, Tomicic M, Vuk T, Sarlija D, Balija M. ABO blood groups and genetic risk factors for thrombosis in Croatian population. Croat Med J. 2009;50:550\u20138. https:\/\/doi.org\/10.3325\/cmj.2009.50.550.","journal-title":"Croat Med J"},{"key":"616_CR24","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1007\/s00392-019-01526-7","volume":"109","author":"K Jobski","year":"2020","unstructured":"Jobski K, Hoffmann F, Herget-Rosenthal S, D\u00f6rks M. Drug interactions with oral anticoagulants in German nursing home residents: comparison between vitamin K antagonists and non-vitamin K antagonist oral anticoagulants based on two nested case-control studies. Clin Res Cardiol. 2020;109:465\u201375. https:\/\/doi.org\/10.1007\/s00392-019-01526-7.","journal-title":"Clin Res Cardiol"},{"key":"616_CR25","doi-asserted-by":"publisher","unstructured":"Steffel J, Verhamme P, Potpara TS, Albaladejo P, Antz M, Desteghe L, Hausler GK, Oldgren J, Reinecke H, Roldan-Schilling V, Rowell N, Sinnaeve P, Collins R, Camm AJ, Heidb\u00fcchel H, ESC Scientific Document Group. The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. Eur Heart J. 2018;39:1330\u201393https:\/\/doi.org\/10.1093\/eurheartj\/ehy136","DOI":"10.1093\/eurheartj\/ehy136"},{"key":"616_CR26","doi-asserted-by":"publisher","first-page":"165","DOI":"10.2217\/cer-2018-0134","volume":"8","author":"M Cerd\u00e1","year":"2019","unstructured":"Cerd\u00e1 M, Cerezo-Manchado JJ, Johansson E, Mart\u00ednez F, Fern\u00e1ndez M, Varela A, Rodr\u00edguez S, Bosch F, Santamar\u00eda A. Facing real-life with direct oral anticoagulants in patients with nonvalvular atrial fibrillation: outcomes from the first observational and prospective study in a Spanish population. J Comp Eff Res. 2019;8:165\u201378. https:\/\/doi.org\/10.2217\/cer-2018-0134.","journal-title":"J Comp Eff Res."},{"key":"616_CR27","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1186\/s12916-015-0322-7","volume":"13","author":"B Guthrie","year":"2015","unstructured":"Guthrie B, Makubate B, Hernandez-Santiago V, Dreischulte T. The rising tide of polypharmacy and drug-drug interactions: population database analysis 1995\u20132010. BMC Med. 2015;13:74. https:\/\/doi.org\/10.1186\/s12916-015-0322-7.","journal-title":"BMC Med"},{"key":"616_CR28","doi-asserted-by":"publisher","first-page":"1179","DOI":"10.1007\/s00508-021-01882-3","volume":"133","author":"T Kere\u0161","year":"2021","unstructured":"Kere\u0161 T, Juki\u0107 I, Svagu\u0161a T, Prka\u010din I, Bingulac-Popovi\u0107 J, Vinkovi\u0107 M, He\u0107imovi\u0107 A, \u017divkovi\u0107 M, Para\u0161ilovac N. A1B and BB blood group genotypes are risk factors for pulmonary embolism. Wiener Klin Wochenschrift. 2021;133:1179\u201385. https:\/\/doi.org\/10.1007\/s00508-021-01882-3.","journal-title":"Wiener Klin Wochenschrift."}],"container-title":["High Blood Pressure & Cardiovascular Prevention"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40292-023-00616-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40292-023-00616-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40292-023-00616-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,13]],"date-time":"2024-03-13T18:48:55Z","timestamp":1710355735000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40292-023-00616-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,8]]},"references-count":28,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,1]]}},"alternative-id":["616"],"URL":"https:\/\/doi.org\/10.1007\/s40292-023-00616-y","relation":{},"ISSN":["1179-1985"],"issn-type":[{"value":"1179-1985","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,8]]},"assertion":[{"value":"12 August 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 November 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 January 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was conducted following the Declaration of Helsinki and approved by the Hospital's Ethics Committee.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Institutional review board statement"}},{"value":"All patients included in the study received both written and oral information about the study and signed written informed consent.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}